Bagsværd, Denmark, 7 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Related Questions
Which insiders (board members, executives, associated persons) were involved and what are their respective ownership stakes?
What is the total volume of shares traded by insiders compared to average daily volume?
Were the transactions executed at a premium or discount to the current market price?
Did any of the board members or executives disclose the reason for the trades (e.g., tax planning, portfolio rebalancing, or material information)?
How do these insider transactions compare to those of previous quarters or years?
How do the insider trading volumes compare with those of key competitors in the pharmaceutical sector?
How many shares were bought or sold by each insider and at what price?
Will the disclosed transactions affect market sentiment or trigger short‑selling activity?
What potential regulatory or legal implications could arise if the trades are deemed non‑compliant with Article 19 of Regulation No. 596/2014?
Is there any pattern or timing (e.g., around earnings release or product launch) that suggests insider knowledge?